Why Healthcare Demands More Than Minimal

Healthcare has a non-negotiable clinical floor. A product is not viable if a clinician cannot legally or safely use it in a medical setting. In Australia, the Therapeutic Goods Administration (TGA) defines these boundaries through strict regulatory pathways that don't allow for "minimal" safety. Our thesis focuses on backing founders who understand that clinical safety is the foundation of commercial success. Over 60% of healthtech pilots fail to reach enterprise adoption because the initial product lacks the integration or compliance features required for a hospital's existing workflow. They validate a concept but fail to build a tool that actually works in a ward.

The Problem with Slow Development Cycles

Capital efficiency is the lifeblood of a pre-seed startup. If you spend six months building a version that no user has touched, you've likely wasted a significant portion of your initial funding. Long development cycles without feedback loops are the primary cause of startup failure. They lead to psychological burnout for founders and a product that misses the market's actual needs. To survive, you must compress the time between ideation and deployment. You need to build your Viable Product in days and forget MVP cycles that stretch into months. This approach allows you to test clinical assumptions with real users before your runway disappears, ensuring you build something that clinicians actually value. The traditional Minimum Viable Product (MVP) focuses on the smallest set of features required to test a hypothesis. In healthtech, this approach often results in "throwaway" code that lacks the security or clinical depth required for actual patient care. A Viable Product (VP) shifts the focus from learning to utility. It represents a functional, secure, and clinically aware system that integrates into the healthcare ecosystem from day one. When you build your Viable Product in days and forget MVP, you prioritise professional-grade tools over experimental prototypes. This approach aligns with the principles of Medicine 3.0, where healthcare is proactive, data-driven, and highly personalised. A VP ensures that every line of code supports this preventative model, rather than just checking a box for a seed round. By focusing on the full value chain immediately, founders avoid the technical debt that usually kills healthtech startups during their first pivot.

The Four Pillars of a Viable Product

A product is only viable if it can survive the rigours of a clinical setting. Dreamoro identifies four essential pillars for any VP:

Comparing the Two Approaches

The difference between an MVP and a VP is the difference between a prototype and a foundation. While an MVP is often discarded after the initial learning phase, the VP serves as the permanent core of the final platform. The Dreamoro thesis prioritises the VP model because it accelerates the path to commercialisation. In a sector where 1,005 healthtech companies are competing for limited clinical attention, being "viable" means being ready for immediate deployment. Startups that build your Viable Product in days and forget MVP find themselves in a stronger position when engaging with health systems. They offer a finished tool rather than a request for feedback. To understand how this strategy fits into a broader go-to-market plan, you can examine our latest industry insights regarding capital-efficient growth. Engineering has fundamentally shifted. AI is no longer a peripheral tool for writing unit tests; it is the primary engine for the entire development roadmap. This shift allows you to build your Viable Product in days and forget MVP frameworks that lead to throwaway code. By treating AI as the core architect rather than a simple assistant, founders can bypass the traditional months of infrastructure setup and boilerplate development. The year 2026 marks the point where manual coding becomes the bottleneck, not the solution, for healthtech founders. Managed development operations now reduce the friction that typically stalls early-stage ventures. Instead of losing sleep over server configurations or database schemas, you can focus on clinical validation. This approach ensures that your technical foundation is robust, scalable and ready for the rigours of a healthcare environment from the first commit.

Automating the Boring Stuff in Healthtech

Healthtech development is notorious for its "boring" but essential hurdles. AI now handles complex data mapping and integration with legacy healthcare systems, such as FHIR and HL7, in a fraction of the time. What once required weeks of manual cross-referencing is now automated through intelligent agents that understand medical data structures. AI-assisted compliance tools also generate the bulk of necessary regulatory documentation, ensuring your technical file remains current without diverting your engineering resources. AI-enabled engineering allows a single developer to perform the work of a five-person team.

Rapid Prototyping vs Rapid Building

The industry is moving beyond "no-code" tools that often fail when faced with strict healthcare security requirements. The new standard is AI-generated "real-code" that is production-ready and fully extensible. Dreamoro Studio uses custom AI agents to build healthtech specific architectures, ensuring that security, privacy and interoperability are baked into the source code from day one. This isn't just about making a mockup; it's about building a defensible asset. To build your Viable Product in days and forget MVP is now a fundamental requirement for staying competitive in the Australian ecosystem. Local founders must deploy with speed to secure clinical partnerships and pilot programmes before international competitors occupy the market. Speed is no longer just an advantage; it is your primary defence against obsolescence. Speed is the primary competitive advantage for any healthtech founder. You can build your Viable Product in days and forget MVP by isolating the Atomic Value Unit: the singular function that delivers immediate clinical or operational utility. This approach bypasses the bloat of traditional development. Before the first line of code is written, you must establish a healthtech go-to-market strategy. This framework ensures your build aligns with specific reimbursement codes, clinical workflows, and procurement cycles. Without this strategic foundation, even the most elegant software will fail to find a foothold in the healthcare ecosystem.

Day 1 and 2: Architecture and Core Logic

The first 48 hours focus on the engine. Do not waste time on peripheral features like password recovery or profile customisation. Instead, map the user journey to identify the critical clinical intervention. This is the precise moment your product improves a patient outcome or removes a bottleneck for a clinician. Use AI-assisted development tools to generate your database schema and security protocols in hours. This stage requires setting regulatory guardrails immediately. In the Australian context, this involves ensuring your architecture aligns with the Australian Privacy Principles and relevant TGA frameworks from the outset. A disciplined, capital-efficient architecture prevents technical debt from accumulating during the rapid build.

Day 3 and 4: Frontend and Integration

Clinical environments demand a specific design language. Software must perform under high-pressure, high-cognitive-load conditions. Apply UX/UI design principles that prioritise clarity and reduce the number of clicks required to reach the Atomic Value Unit. By day four, your focus shifts to integration. Connect your VP to necessary healthcare data sources using FHIR-compliant APIs or HL7 standards to ensure interoperability. The final sprint is not about a polished launch; it's about validation. Test the functional VP with a cohort of 5 to 10 friendly clinicians or industry users. Their feedback on the core logic is the only data that matters. This methodology allows you to build your Viable Product in days and forget MVP models that often result in over-engineered products that the market doesn't actually want. Building at this pace requires a partner who understands both the code and the clinical context. Hiring an internal engineering team at the pre-seed stage is often a strategic error. Founders frequently spend six months recruiting a CTO and developers, only to find their initial capital depleted before a line of code is tested by a clinician. A digital health studio model eliminates this friction. By accessing a pre-existing ecosystem of developers, regulatory experts, and designers, you can build your Viable Product in days and forget MVP approaches that fail to meet clinical standards. The studio model offers shared intelligence. Because the team has built similar architectures across dozens of healthtech projects, they don't start from zero. This reduces technical debt and ensures the product is capital-efficient from the first sprint. It allows you to focus on clinical validation and market entry while the studio provides the technical foundation needed to reach the next startup fundraising stages. This approach shifts the risk from the founder to a proven execution framework, ensuring that the software is built to scale within the complexities of the healthcare system.

The Dreamoro Advantage for Healthtech Founders

Dreamoro operates with a "Two arms. One mission." philosophy. This integrates Dreamoro Ventures with hands-on product engineering through the Dreamoro Studio. This structure provides the technical and strategic muscle solo founders lack, bridging the gap between a conceptual idea and a market-ready asset. Our mapping of 1,005 healthtech companies shows that those who bypass the traditional MVP phase to launch VPs with built-in regulatory compliance reach Series A significantly faster than those following traditional paths. By providing an integrated platform, Dreamoro ensures that your product is not just a prototype, but a defensible piece of healthcare infrastructure.

Your Next Steps Toward a Viable Product

Evaluate your current development roadmap. If your timeline to market exceeds 120 days, your strategy may be too slow for the 2026 market. Defensible strategic positioning requires more than just software; it requires a product that integrates into the existing healthcare full value chain from day one. You can begin this process by contacting the team to see if your project aligns with the Dreamoro investment thesis. We back the founders building the future of healthcare by providing the intelligence and execution speed necessary to build your Viable Product in days and forget MVP limitations. The goal is to move beyond the build phase and into a position of market leadership through disciplined, expert-led execution. The era of the unfinished MVP is over. In a sector where clinical efficacy and regulatory compliance are non-negotiable, you must deliver a product that is complete rather than just functional. By leveraging AI-first engineering and a structured 4-day roadmap, you can build your Viable Product in days and forget MVP hurdles that stall traditional startups. This approach ensures your technology is defensible and ready for integration into the complex healthcare ecosystem from day one. Success in Medicine 3.0 requires more than just code; it demands deep domain intelligence. Dreamoro Studio provides this through a proprietary database of 1,005 healthtech companies mapped across the global ecosystem. Our team combines Red Dot award-winning product design with a specialist focus on AI-enabled health and prevention technology. We help you bypass common pitfalls in the regulatory pathway and the broader healthcare value chain. Partner with Dreamoro Studio to build your Viable Product and secure your position as an architect of the future of healthcare. Your vision for better health outcomes deserves a foundation built for scale.

What is the main difference between an MVP and a Viable Product?

An MVP focuses on technical feasibility, while a Viable Product prioritises clinical utility and system integration from day one. Traditional MVPs often strip away essential healthcare features, leaving a product that cannot survive a hospital environment. To build your Viable Product in days and forget MVP, you must focus on creating a tool that solves a specific clinical workflow issue rather than just testing a basic feature set.

Is it really possible to build a healthtech product in just a few days?

Rapid prototyping is possible through AI-first engineering and pre-built healthtech infrastructure. By utilising existing compliant modules and automated code generation, the initial build time reduces from months to approximately 10 to 14 days. This speed allows founders to move directly into clinical validation, which is where the real value of a healthtech venture is proven through actual user data and patient outcomes.

How does AI-first engineering handle clinical safety and regulatory requirements?

AI-first engineering automates the underlying technical architecture, while clinical safety is managed through established regulatory frameworks and human oversight. Dreamoro uses a structured approach where AI generates the code, but the clinical logic follows ISO 13485 standards. This ensures that the speed of development doesn't compromise patient safety or data privacy requirements, maintaining a clear audit trail for future TGA or FDA submissions.

Why do most healthtech MVPs fail when they reach the clinical pilot stage?

Approximately 90% of healthtech MVPs fail at the pilot stage because they lack interoperability with existing electronic health records. These products are often built in isolation, ignoring the complex procurement and clinical safety standards required by hospitals. A Viable Product avoids this by incorporating HL7 or FHIR standards at the earliest stage of development, ensuring the software actually works within the healthcare ecosystem.

Do I need a technical co-founder if I work with a digital health studio?

You don't necessarily need a technical co-founder if you partner with a specialist digital health studio that provides deep engineering and regulatory expertise. This model allows founders to focus on clinical validation and market entry while the studio manages the technical roadmap. It's a capital-efficient way to bridge the gap between an idea and a market-ready solution without giving away significant equity early on.

How much capital do I need to build a Viable Product compared to a traditional build?

Building a Viable Product typically requires 60% less capital than traditional software development cycles. In 2023, over $856 million was invested in Australian healthtech, yet many startups exhausted their initial seed funding on technical builds that never reached the clinic. By focusing on a rapid, AI-enabled build, you preserve capital for the more expensive regulatory and clinical trial phases that follow the initial development.

What happens after the initial product is built in days?

Once the product is built, the focus shifts immediately to clinical validation and user feedback within a real-world setting. This phase involves testing the product with clinicians to ensure it fits their daily workflow and provides measurable health outcomes. Success in this stage is what allows a founder to build your Viable Product in days and forget MVP as a long-term strategy for sustainable growth.

Back to BlogARTICLE

Build Your Viable Product in Days and Forget MVP: A Healthtech Founder Strategy

For healthtech founders: build your Viable Product in days and forget MVP. Discover an AI-first strategy to accelerate clinical adoption and reduce burn rate.

Klaus Bartosch · 18 April 2026 · 15 min read

Frequently Asked Questions

Klaus Bartosch

CEO, Founder & Managing Partner